Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
Profitability
This table compares Amylyx Pharmaceuticals and Ocular Therapeutix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -55.69% | -50.73% |
| Ocular Therapeutix | -558.24% | -64.28% | -48.15% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Amylyx Pharmaceuticals and Ocular Therapeutix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 1 | 2 | 8 | 1 | 2.75 |
| Ocular Therapeutix | 1 | 1 | 12 | 0 | 2.79 |
Institutional and Insider Ownership
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Amylyx Pharmaceuticals and Ocular Therapeutix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $87.37 million | 17.13 | -$144.74 million | ($1.50) | -8.97 |
| Ocular Therapeutix | $52.04 million | 36.78 | -$265.94 million | ($1.46) | -5.99 |
Amylyx Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Amylyx Pharmaceuticals has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
Summary
Ocular Therapeutix beats Amylyx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
